Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) has issued an update.
CStone Pharmaceuticals has announced the composition of its board of directors and their respective roles within the company. This announcement highlights the company’s leadership structure, which includes a mix of executive, non-executive, and independent directors, and outlines the membership of various board committees, reflecting the company’s commitment to governance and strategic oversight.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing and commercializing innovative oncology therapies.
Average Trading Volume: 22,971,684
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.28B
Learn more about 2616 stock on TipRanks’ Stock Analysis page.